Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Oceanpine Capital

Investor type Venture Capital
Founders David Liguang Chenn


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 32
Average round size
The average size of a deal this fund participated in
Portfolio companies 28
Rounds per year 6.40
Lead investments 4
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 1
Key employees 1
Stages of investment
Early Stage Venture
Late Stage Venture

Areas of investment

  • Biotechnology
  • Health Care
  • Biopharma
  • Medical
  • Artificial Intelligence

Oceanpine Capital appeared to be the VC, which was created in 2017. The company was established in Asia in Hong Kong. The main office of represented VC is situated in the Central.

We can highlight the next thriving fund investment areas, such as Oil and Gas, Semiconductor. The fund has no exact preference in a number of founders of portfolio startups. In case when startup counts 3 of the founder, the chance for it to get the investment is meager. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Horizon Robotics, Tiger Brokers, For fund there is no match between the location of its establishment and the land of its numerous investments - China.

The average startup value when the investment from Oceanpine Capital is more than 1 billion dollars. The usual things for fund are deals in the range of more than 100 millions dollars. The fund is generally included in 2-6 deals every year. The top activity for fund was in 2018. The increased amount of exits for fund were in 2019. Opposing the other organizations, this Oceanpine Capital works on 9 percentage points less the average amount of lead investments.

The standard case for the fund is to invest in rounds with 7-8 partakers. Despite the Oceanpine Capital, startups are often financed by ZhenFund, Yunqi Partners, Wu Capital. The meaningful sponsors for the fund in investment in the same round are Matrix Partners China, Lilly Asia Ventures, 3E Bioventures. In the next rounds fund is usually obtained by Matrix Partners China, Lilly Asia Ventures, Korea Investment Partners.

The fund was created by David Liguang Chenn Chenn. Besides them, we counted 1 critical employee of this fund in our database.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Oceanpine Capital:
Typical Co-investors
Oceanpine Capital is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Oceanpine Capital:
There are no funds here. If we find new data, we will add it here.

Funds with similar focus

Funds from China
Funds with similar focus located in China:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
2500 Bachman Ventures Atlanta, Georgia, United States
30Ventures Madison, United States, Wisconsin
Axioma Ventures Green Bay, United States, Wisconsin
BlueCap Partners Austin, Texas, United States
Burrill Agbio Capital Fund California, San Francisco, United States
CIT VentureCapital Morristown, New Jersey, United States
Epilepsy Louisiana, Maryland, United States
Kejora Ventures Indonesia, Jakarta, Jakarta Raya
Loeb Enterprises New York, New York, United States
MetaBrand Capital Edison, New Jersey, United States
Orient Securities China, Shanghai
Posco Seoul, Seoul-t'ukpyolsi, South Korea
SEN CORPORATION Japan Japan, Tokyo
Simpleweb Bristol, England, United Kingdom
SND Ventures Group China, Jiangsu, Suzhou
Soul Capital Auckland, Auckland, New Zealand
TI Holdings -
Vision Knight Capital China, Shanghai
Yipu Capital -

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation


Artificial Intelligence
Machine Learning
10 Aug 2022 Shanghai, China


Autonomous Vehicles
Information Technology
Intelligent Systems
31 May 2022 Beijing, Beijing, China

Shenzhen Shifeng

$15M10 Mar 2022 Shenzhen, Guangdong, China


Cloud Infrastructure
Information Technology
$63M25 Feb 2022 Hangzhou, Zhejiang, China

Lianshu Technology

$15M23 Feb 2022 Nanjing, Jiangsu, China


Health Care
Health Diagnostics
Professional Services
24 Dec 2021 Beijing, Beijing, China

Yuchuang Semiconductor

Application Specific Integrated Circuit (ASIC)
$15M21 Dec 2021 Shenzhen, Guangdong, China

Chipone Technology

Product Design
$1B15 Dec 2021 Beijing, Beijing, China


Health Care
Product Research
$50M09 Sep 2021 Nansha District, Guangdong Province, China
SVOLT Energy Closes RMB10.28 Billion Series B Financing

– SVOLT Energy Technology Co., Ltd. is a Beijing, China-based EV battery manufacturer.
– Company raised a total amount of RMB 10.28 billion ($US 1.58 billion) in Series B funding.
– The round was led by Bank of China Group Investment (BOCGI), Country Garden Venture Capital, Shenzhen Capital Group (SCGC), CCB Investment, IDG Capital, Sany, Xiaomi Corporation, Oceanpine Capital, CHINA RENAISSANCE among others.
– The Series B funds will be mainly used for R&D of new technologies and construction of new factories.

Immune-Onc Therapeutics Announces $73 Million in Series B1 and B2 Financing to Advance its Portfolio of Novel Immunotherapies in Blood Cancers and Solid Tumors

– Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting immunosuppressive myeloid checkpoints today announced the closing of a $73 million Series B1 and B2 financing.
– The round was led by Oceanpine Capital with participation from additional new investors including Octagon Capital and Sphera Healthcare, and existing investors, including Northern Light Venture Capital and Vivo Capital.
– In conjunction with this round of financing, Oceanpine CEO and managing partner Dave Chenn joins the Immune-Onc Board of Directors.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Oceanpine Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: